The coronary circulation in acute myocardial ischaemia/reperfusion injury: A target for cardioprotection

Cardiovascular Research

Volumn 115, Issue 7, 2019, Pages 1143-1155

  Hausenloy, Derek J ^a,b,c,d,e,f   Chilian, William ^g   Crea, Filippo ^h   Davidson, Sean M ^d   Ferdinandy, Peter ^i,j   Garcia Dorado, David ^k,l   Van Royen, Niels ^m   Schulz, Rainer ⁿ   Heusch, Gerd ^o  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DEPARTMENT OF CARDIOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^f ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^g Northeastern Ohio Medical University   (United States)

^h FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

ⁱ SEMMELWEIS UNIVERSITY   (Hungary)

^j PHARMAHUNGARY GROUP   (Hungary)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l Instituto de Salud Carlos III ^*  (Spain)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ JUSTUS LIEBIG UNIVERSITY   (Germany)

^o UNIVERSITY HOSPITAL ESSEN   (Germany)

more..

Author keywords

Cardioprotection; Coronary circulation; Ischaemia; Microvascular obstruction; Reperfusion

Indexed keywords

CARDIOVASCULAR AGENT;

ANGIOGENESIS; BLEEDING; BLOOD VESSEL OCCLUSION; CLINICAL ASSESSMENT; COMBINATION DRUG THERAPY; COMORBIDITY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY COLLATERAL CIRCULATION; EDEMA; ENDOTHELIUM; GLYCOCALYX; HEART INFARCTION PREVENTION; HEART PROTECTION; HUMAN; INVASIVE PROCEDURE; MICROANGIOPATHY; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NO REFLOW PHENOMENON; NON INVASIVE PROCEDURE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; ADVERSE EVENT; ANIMAL; CARDIAC MUSCLE; COLLATERAL CIRCULATION; DRUG EFFECT; HEART INFARCTION; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; METABOLISM; MICROCIRCULATION; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; CARDIOVASCULAR AGENTS; COLLATERAL CIRCULATION; CORONARY CIRCULATION; HUMANS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MICROCIRCULATION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; NO-REFLOW PHENOMENON; TREATMENT OUTCOME;

EID: 85066487438     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvy286     Document Type: Review

References (200)

1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
2. Ibanez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol 2015;65:1454-1471.
3. Kleinbongard P, Amanakis G, Skyschally A, Heusch G. Reflection of cardioprotection by remote ischemic perconditioning in attenuated ST-segment elevation during ongoing coronary occlusion in pigs: evidence for cardioprotection from ischemic injury. Circ Res 2018;122:1102-1108.
4. Hausenloy DJ, Botker HE, Engstrom T, Erlinge D, Heusch G, Ibanez B, Kloner RA, Ovize M, Yellon DM, Garcia-Dorado D. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: Trials and tribulations. Eur Heart J 2017;38:935-941.
5. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: A continual challenge. Eur Heart J 2017;38: 774-784.
6. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2018; doi: 10.1093/eurheartj/ehy462 [Epub ahead of print].
7. Hausenloy DJ, Erik BH, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, Lecour S, van Laake LW, Madonna R, Ruiz-Meana M, Schulz R, Sluijter JP, Yellon DM, Ovize M. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2013;98:7-27.
8. Bulluck H, Yellon DM, Hausenloy DJ. Reducing myocardial infarct size: challenges and future opportunities. Heart 2016;102:341-348.
9. Hausenloy DJ, Garcia-Dorado D, Botker HE, Davidson SM, Downey J, Engel FB, Jennings R, Lecour S, Leor J, Madonna R, Ovize M, Perrino C, Prunier F, Schulz R, Sluijter JPG, van Laake LW, Vinten-Johansen J, Yellon DM, Ytrehus K, Heusch G, Ferdinandy P. Novel targets and future strategies for acute cardioprotection: position paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovasc Res 2017;113:564-585.
10. Heusch G. Critical issues for the translation of cardioprotection. Circ Res 2017;120: 1477-1486.
11. Heusch G. The coronary circulation as a target of cardioprotection. Circ Res 2016; 118:1643-1658.
12. Partida RA, Libby P, Crea F, Jang IK. Plaque erosion: A new in vivo diagnosis and a potential major shift in the management of patients with acute coronary syndromes. Eur Heart J 2018;39:2070-2076.
13. Heusch G, Skyschally A, Kleinbongard P. Coronary microembolization and microvascular dysfunction. Int J Cardiol 2018;258:17-23.
14. Mills I, Fallon JT, Wrenn D, Sasken H, Gray W, Bier J, Levine D, Berman S, Gilson M, Gewirtz H. Adaptive responses of coronary circulation and myocardium to chronic reduction in perfusion pressure and flow. Am J Physiol 1994;266: H447-H457.
15. Sorop O, Merkus D, de Beer VJ, Houweling B, Pistea A, McFalls EO, Boomsma F, van Beusekom HM, van der Giessen WJ, VanBavel E, Duncker DJ. Functional and structural adaptations of coronary microvessels distal to a chronic coronary artery stenosis. Circ Res 2008;102:795-803.
16. Dorge H, Neumann T, Behrends M, Skyschally A, Schulz R, Kasper C, Erbel R, Heusch G. Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation. Am J Physiol Heart Circ Physiol 2000;279:H2587-H2592.
17. Thielmann M, DöRge H, Martin C, Belosjorow S, Schwanke U, van de Sand A, Konietzka I, BüChert A, KrüGer A, Schulz R, Heusch G, Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-Alpha, and sphingosine. Circ Res 2002;90:807-813.
18. Herrmann J, Haude M, Lerman A, Schulz R, Volbracht L, Ge J, Schmermund A, Wieneke H, von BC, Eggebrecht H, Baumgart D, Heusch G, Erbel R. Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation. Circulation 2001;103:2339-2345.
19. Leineweber K, Bose D, Vogelsang M, Haude M, Erbel R, Heusch G. Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. J Am Coll Cardiol 2006;47:981-986.
20. Kleinbongard P, Bose D, Baars T, Mohlenkamp S, Konorza T, Schoner S, Elter-Schulz M, Eggebrecht H, Degen H, Haude M, Levkau B, Schulz R, Erbel R, Heusch G. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res 2011;108:344-352.
21. Skyschally A, Schulz R, Erbel R, Heusch G. Reduced coronary and inotropic reserves with coronary microembolization. Am J Physiol Heart Circ Physiol 2002;282: H611-H614.
22. Stempien-Otero A, Karsan A, Cornejo CJ, Xiang H, Eunson T, Morrison RS, Kay M, Winn R, Harlan J. Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J Biol Chem 1999;274:8039-8045.
23. Maxwell L, Gavin JB. The role of post-ischaemic reperfusion in the development of microvascular incompetence and ultrastructural damage in the myocardium. Basic Res Cardiol 1991;86:544-553.
24. Kasseckert SA, Schafer C, Kluger A, Gligorievski D, Tillmann J, Schluter KD, Noll T, Sauer H, Piper HM, Abdallah Y. Stimulation of cGMP signalling protects coronary endothelium against reperfusion-induced intercellular gap formation. Cardiovasc Res 2009;83:381-387.
25. Scotland RS, Cohen M, Foster P, Lovell M, Mathur A, Ahluwalia A, Hobbs AJ. Ctype natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression. Proc Natl Acad Sci USA 2005;102: 14452-14457.
26. Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, McSharry H, Iwakura A, Yoon YS, Himes N, Burstein D, Doukas J, Soll R, Losordo D, Cheresh D. Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004;113:885-894.
27. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGFmediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004;167:223-229.
28. Betgem RP, de Waard GA, Nijveldt R, Beek AM, Escaned J, van RN. Intramyocardial haemorrhage after acute myocardial infarction. Nat Rev Cardiol 2015;12:156-167.
29. Liu Y, Lian K, Zhang L, Wang R, Yi F, Gao C, Xin C, Zhu D, Li Y, Yan W, Xiong L, Gao E, Wang H, Tao L. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. Basic Res Cardiol 2014;109:415.
30. Galaup A, Gomez E, Souktani R, Durand M, Cazes A, Monnot C, Teillon J, Le JS, Bouleti C, Briois G, Philippe J, Pons S, Martin V, Assaly R, Bonnin P, Ratajczak P, Janin A, Thurston G, Valenzuela DM, Murphy AJ, Yancopoulos GD, Tissier R, Berdeaux A, Ghaleh B, Germain S. Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation 2012;125:140-149.
31. Mollenhauer M, Friedrichs K, Lange M, Gesenberg J, Remane L, Kerkenpaß C, Krause J, Schneider J, Ravekes T, Maass M, Halbach M, Peinkofer G, Saric T, Mehrkens D, Adam M, Deuschl FG, Lau D, Geertz B, Manchanda K, Eschenhagen T, Kubala L, Rudolph TK, Wu Y, Tang WHW, Hazen SL, Baldus S, Klinke A, Rudolph V. Myeloperoxidase mediates postischemic arrhythmogenic ventricular remodeling. Circ Res 2017;121:56-70.
32. Bitencourt CS, Bessi VL, Huynh DN, Menard L, Lefebvre JS, Levesque T, Hamdan L, Sohouhenou F, Faccioli LH, Borgeat P, Marleau S. Cooperative role of endogenous leucotrienes and platelet-Activating factor in ischaemia-reperfusion-mediated tissue injury. J Cell Mol Med 2013;17:1554-1565.
33. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005;437:497-504.
34. Feng Y, Venema VJ, Venema RC, Tsai N, Behzadian MA, Caldwell RB. VEGF-induced permeability increase is mediated by caveolae. Invest Ophthalmol Vis Sci 1999;40: 157-167.
35. Lee SW, Won JY, Lee HY, Lee HJ, Youn SW, Lee JY, Cho CH, Cho HJ, Oh S, Chae IH, Kim HS. Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardiac integrin-b1/ERK/caspase-9 phosphorylation cascade. Mol Med 2011;17:1095-1106.
36. Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, O?Farrell FM, Buchan AM, Lauritzen M, Attwell D. Capillary pericytes regulate cerebral blood flow in health and disease. Nature 2014;508:55-60.
37. Nees S, Weiss DR, Senftl A, Knott M, Forch S, Schnurr M, Weyrich P, Juchem G. Isolation, bulk cultivation, and characterization of coronary microvascular pericytes: The second most frequent myocardial cell type in vitro. Am J Physiol Heart Circ Physiol 2012;302:H69-H84.
38. O?Farrell FM, Mastitskaya S, Hammond-Haley M, Freitas F, Wah WR, Attwell D. Capillary pericytes mediate coronary no-reflow after myocardial ischaemia. Elife 2017;6. pii:e29280. doi:10.7554/eLife.29280.
39. Becker BF, Chappell D, Jacob M. Endothelial glycocalyx and coronary vascular permeability: The fringe benefit. Basic Res Cardiol 2010;105:687-701.
40. van den Berg BM, Vink H, Spaan JA. The endothelial glycocalyx protects against myocardial edema. Circ Res 2003;92:592-594.
41. Chappell D, Dorfler N, Jacob M, Rehm M, Welsch U, Conzen P, Becker BF. Glycocalyx protection reduces leukocyte adhesion after ischemia/reperfusion. Shock 2010;34:133-139.
42. Chappell D, Brettner F, Doerfler N, Jacob M, Rehm M, Bruegger D, Conzen P, Jacob B, Becker BF. Protection of glycocalyx decreases platelet adhesion after ischaemia/reperfusion: An animal study. Eur J Anaesthesiol 2014;31:474-481.
43. Chappell D, Hofmann-Kiefer K, Jacob M, Rehm M, Briegel J, Welsch U, Conzen P, Becker BF. TNF-Alpha induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin. Basic Res Cardiol 2009;104:78-89.
44. Bruegger D, Rehm M, Jacob M, Chappell D, Stoeckelhuber M, Welsch U, Conzen P, Becker BF. Exogenous nitric oxide requires an endothelial glycocalyx to prevent postischemic coronary vascular leak in guinea pig hearts. Crit Care 2008;12:R73.
45. Garcia-Dorado D, Andres-Villarreal M, Ruiz-Meana M, Inserte J, Barba I. Myocardial edema: A translational view. J Mol Cell Cardiol 2012;52:931-939.
46. Garcia-Dorado D, Theroux P, Munoz R, Alonso J, Elizaga J, Fernandez-Aviles F, Botas J, Solares J, Soriano J, Duran JM. Favorable effects of hyperosmotic reperfusion on myocardial edema and infarct size. Am J Physiol 1992;262:H17-H22.
47. Andres-Villarreal M, Barba I, Poncelas M, Inserte J, Rodriguez-Palomares J, Pineda V, Garcia-Dorado D. Measuring water distribution in the heart: preventing edema reduces ischemia-reperfusion injury. J Am Heart Assoc 2016;5. pii:e003843.
48. Inserte J, Garcia-Dorado D, Hernando V, Soler-Soler J. Calpain-mediated impairment of Na?/K?-ATPase activity during early reperfusion contributes to cell death after myocardial ischemia. Circ Res 2005;97:465-473.
49. Fernandez-Jimenez R, Sanchez-Gonzalez J, Aguero J, Garcia-Prieto J, Lopez-Martin GJ, Garcia-Ruiz JM, Molina-Iracheta A, Rossello X, Fernandez-Friera L, Pizarro G, Garcia-Alvarez A, Dall?armellina E, Macaya C, Choudhury RP, Fuster V. Ibanez B. Myocardial edema after ischemia/reperfusion is not stable and follows a bimodal pattern: imaging and histological tissue characterization. J Am Coll Cardiol 2015;65: 315-323.
50. Fernandez-Jimenez R, Barreiro-Perez M, Martin-Garcia A, Sanchez-Gonzalez J, Aguero J, Galan-Arriola C, Garcia-Prieto J, Diaz-Pelaez E, Vara P, Martinez I, Zamarro I, Garde B, Sanz J, Fuster V, Sanchez PL, Ibanez B. Dynamic edematous response of the human heart to myocardial infarction: implications for assessing myocardial area at risk and salvage. Circulation 2017;136:1288-1300.
51. Walsh TG, Poole AW. Do platelets promote cardiac recovery after myocardial infarction: roles beyond occlusive ischemic damage. Am J Physiol Heart Circ Physiol 2018;314:H1043-H1048.
52. Pagel O, Walter E, Jurk K, Zahedi RP. Taking the stock of granule cargo: platelet releasate proteomics. Platelets 2017;28:119-128.
53. Theilmeier G, Schmidt C, Herrmann J, Keul P, SchäFers M, Herrgott I, Mersmann J, Larmann J, Hermann S, Stypmann J, Schober O, Hildebrand R, Schulz R, Heusch G, Haude M, von Wnuck LK, Herzog C, Schmitz M, Erbel R, Chun J, Levkau B. Highdensity lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006;114:1403-1409.
54. Keul P, van Borren MM, Ghanem A, Muller FU, Baartscheer A, Verkerk AO, Stumpel F, Schulte JS, Hamdani N, Linke WA, van LP, Matus M, Schmitz W, Stypmann J, Tiemann K, Ravesloot JH, Alewijnse AE, Hermann S, Spijkers LJ, Hiller KH, Herr D, Heusch G, Schafers M, Peters SL, Chun J, Levkau B. Sphingosine-1-phosphate receptor 1 regulates cardiac function by modulating Ca2p sensitivity and Na?/H? exchange and mediates protection by ischemic preconditioning. J Am Heart Assoc 2016;5. pii:e003393. doi:10.1161/JAHA.116.003393.
55. Karliner JS, Honbo N, Summers K, Gray MO, Goetzl EJ. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2001;33:1713-1717.
56. Zhang J, Honbo N, Goetzl EJ, Chatterjee K, Karliner JS, Gray MO. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol 2007;293: H3150-H3158.
57. Penna C, Bassino E, Alloatti G. Platelet activating factor: The good and the bad in the ischemic/reperfused heart. Exp Biol Med (Maywood) 2011;236:390-401.
58. Russo I, Femmino S, Barale C, Tullio F, Geuna S, Cavalot F, Pagliaro P, Penna C. Cardioprotective properties of human platelets are lost in uncontrolled diabetes mellitus: A study in isolated rat hearts. Front Physiol 2018;9:875.
59. Battinelli EM, Markens BA, Italiano JE Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 2011;118:1359-1369.
60. Pearson PJ, Schaff HV, Vanhoutte PM. Acute impairment of endothelium-dependent relaxations to aggregating platelets following reperfusion injury in canine coronary arteries. Circ Res 1990;67:385-393.
61. McDonagh PF. Platelets reduce coronary microvascular permeability to macromolecules. Am J Physiol 1986;251:H581-H587.
62. Yang BC, Virmani R, Nichols WW, Mehta JL. Platelets protect against myocardial dysfunction and injury induced by ischemia and reperfusion in isolated rat hearts. Circ Res 1993;72:1181-1190.
63. Heindl B, Zahler S, Welsch U, Becker BF. Disparate effects of adhesion and degranulation of platelets on myocardial and coronary function in postischaemic hearts. Cardiovasc Res 1998;38:383-394.
64. Mirabet M, Garcia-Dorado D, Inserte J, Barrabes JA, Lidon RM, Soriano B, Azevedo M, Padilla F, Agullo L, Ruiz-Meana M, Massaguer A, Pizcueta P, Soler-Soler J. Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts. Am J Physiol Heart Circ Physiol 2002;283:H1134-H1141.
65. Barrabes JA, Inserte J, Mirabet M, Quiroga A, Hernando V, Figueras J, Garcia-Dorado D. Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost 2010;104:128-135.
66. Botker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di LF, Di SM, Efentakis P, Femmino S, Garcia-Dorado D, Giricz Z, Ibanez B, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuhauser M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schluter KD, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol 2018;113:39.
67. Barrabes JA, Garcia-Dorado D, Mirabet M, Lidon RM, Soriano B, Ruiz-Meana M, Pizcueta P, Blanco J, Puigfel Y, Soler-Soler J. Lack of effect of glycoprotein IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs. J Am Coll Cardiol 2002;39: 157-165.
68. Pachel C, Mathes D, Arias-Loza AP, Heitzmann W, Nordbeck P, Deppermann C, Lorenz V, Hofmann U, Nieswandt B, Frantz S. Inhibition of platelet GPVI protects against myocardial ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 2016;36: 629-635.
69. Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV. Platelet P2Y(1)(2) blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther 2013;18:251-262.
70. Krug A, de Rochemont Du Mesnil, Korb G. Blood supply of the myocardium after temporary coronary occlusion. Circ Res 1966;19:57-62.
71. Heusch G, Kleinbongard P, Skyschally A. Myocardial infarction and coronary microvascular obstruction: An intimate, but complicated relationship. Basic Res Cardiol 2013;108:380.
72. Kloner RA, King KS, Harrington M. No-reflow phenomenon in heart and brain. Am J Physiol Heart Circ Physiol 2018;315:H550-H562.
73. Skyschally A, Amanakis G, Neuhauser M, Kleinbongard P, Heusch G. Impact of electrical defibrillation on infarct size and no-reflow in pigs subjected to myocardial ischemia-reperfusion without and with ischemic conditioning. Am J Physiol Heart Circ Physiol 2017;313:H871-H878.
74. Hale SL, Herring MJ, Kloner RA. Delayed treatment with hypothermia protects against the no-reflow phenomenon despite failure to reduce infarct size. J Am Heart Assoc 2013;2:e004234.
75. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J 2016;37:1024-1033.
76. Eitel I, de Waha S, Wohrle J, Fuernau G, Lurz P, Pauschinger M, Desch S, Schuler G, Thiele H. Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. J Am Coll Cardiol 2014;64:1217-1226.
77. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, Matsui H, Toki Y, Ito T, Hayakawa T. Angiographic no-reflow phenomenon as a predictor of adverse long-Term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36:1202-1209.
78. van ?t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998;97:2302-2306.
79. Niccoli G, Cosentino N, Spaziani C, Fracassi F, Tarantini G, Crea F. No-reflow: incidence and detection in the cath-lab. Curr Pharm Des 2013;19:4564-4575.
80. Bulluck H, Foin N, Tan JW, Low AF, Sezer M, Hausenloy DJ. Invasive assessment of the coronary microcirculation in reperfused ST-segment-elevation myocardial infarction patients: where do we stand? Circ Cardiovasc Interv 2017;10. pii:e004373. doi:10.1161/CIRCINTERVENTIONS.116.004373.
81. Yamamuro A, Akasaka T, Tamita K, Yamabe K, Katayama M, Takagi T, Morioka S. Coronary flow velocity pattern immediately after percutaneous coronary intervention as a predictor of complications and in-hospital survival after acute myocardial infarction. Circulation 2002;106:3051-3056.
82. van de Hoef TP, Bax M, Meuwissen M, Damman P, Delewi R, de Winter RJ, Koch KT, Schotborgh C, Henriques JP, Tijssen JG, Piek JJ. Impact of coronary microvascular function on long-Term cardiac mortality in patients with acute ST-segmentelevation myocardial infarction. Circ Cardiovasc Interv 2013;6:207-215.
83. Fahrni G, Wolfrum M, De Maria GL, Cuculi F, Dawkins S, Alkhalil M, Patel N, Forfar JC, Prendergast BD, Choudhury RP, Channon KM, Banning AP, Kharbanda RK. Index of microcirculatory resistance at the time of primary percutaneous coronary intervention predicts early cardiac complications: insights from the OxAMI (Oxford Study in Acute Myocardial Infarction) cohort. J Am Heart Assoc 2017;6. pii:e005409. doi:10.1161/JAHA.116.005409.
84. Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 2004;110:e506-e510.
85. Infusino F, Niccoli G, Fracassi F, Roberto M, Falcioni E, Lanza GA, Crea F. The central role of conventional 12-lead ECG for the assessment of microvascular obstruction after percutaneous myocardial revascularization. J Electrocardiol 2014;47:45-51.
86. Galiuto L, Garramone B, Scara A, Rebuzzi AG, Crea F, La TG, Funaro S, Madonna M, Fedele F, Agati L. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. J Am Coll Cardiol 2008;51:552-559.
87. Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MB, Umans VA, Algra PR, Twisk JW, van Rossum AC. Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury. J Am Coll Cardiol 2008;52:181-189.
88. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765-772.
89. Bulluck H, Dharmakumar R, Arai AE, Berry C, Hausenloy DJ. Cardiovascular magnetic resonance in acute ST-segment-elevation myocardial infarction: recent advances, controversies, and future directions. Circulation 2018;137:1949-1964.
90. Jennings R, Sommers H, Smyth G, Lack H, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960;70:68-78.
91. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496-1508.
92. Fujiwara H, Onodera T, Tanaka M, Fujiwara T, Wu DJ, Kawai C, Hamashima Y. A clinicopathologic study of patients with hemorrhagic myocardial infarction treated with selective coronary thrombolysis with urokinase. Circulation 1986;73:749-757.
93. Ganame J, Messalli G, Dymarkowski S, Rademakers FE, Desmet W, Van De WF, Bogaert J. Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J 2009;30:1440-1449.
94. Carrick D, Haig C, Ahmed N, McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay MM, Davie A, Mahrous A, Mordi I, Rauhalammi S, Sattar N, Welsh P, Radjenovic A, Ford I, Oldroyd KG, Berry C. Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. Circ Cardiovasc Imaging 2016;9:e004148.
95. Amier RP, Tijssen RYG, Teunissen PFA, Fernandez-Jimenez R, Pizarro G, Garcia-Lunar I, Bastante T, van de Ven PM, Beek AM, Smulders MW, Bekkers SCAM, van RN, Ibanez B, Nijveldt R. Predictors of intramyocardial hemorrhage after reperfused ST-segment elevation myocardial infarction. J Am Heart Assoc 2017;6. pii:e005651. doi:10.1161/JAHA.117.005651.
96. Wang G, Yang HJ, Kali A, Cokic I, Tang R, Xie G, Yang Q, Francis J, Li S, Dharmakumar R. Influence of myocardial hemorrhage on staging of reperfused myocardial infarctions with T2 cardiac magnetic resonance imaging: insights into the dependence on infarction type with ex vivo validation. JACC Cardiovasc Imaging 2018;S1936-878X(18)30128-1. doi:10.1016/j.jcmg.2018.01.018 [Epub ahead of print].
97. Bulluck H, Rosmini S, Abdel-Gadir A, White SK, Bhuva AN, Treibel TA, Fontana M, Ramlall M, Hamarneh A, Sirker A, Herrey AS, Manisty C, Yellon DM, Kellman P, Moon JC, Hausenloy DJ. Residual myocardial iron following intramyocardial hemorrhage during the convalescent phase of reperfused ST-segment-elevation myocardial infarction and adverse left ventricular remodeling. Circ Cardiovasc Imaging 2016; 9. pii:e004940.
98. Higginson LA, White F, Heggtveit HA, Sanders TM, Bloor CM, Covell JW. Determinants of myocardial hemorrhage after coronary reperfusion in the anesthetized dog. Circulation 1982;65:62-69.
99. Mathey DG, Schofer J, Kuck KH, Beil U, Kloppel G. Transmural, haemorrhagic myocardial infarction after intracoronary streptokinase. Clinical, angiographic, and necropsy findings. Br Heart J 1982;48:546-551.
100. Hollander MR, de Waard GA, Konijnenberg LS, Meijer-van Putten RM, van den Brom CE, Paauw N, de Vries HE, van de Ven PM, Aman J, Van Nieuw-Amerongen GP, Hordijk PL, Niessen HW, Horrevoets AJ, van RN. Dissecting the effects of ischemia and reperfusion on the coronary microcirculation in a rat model of acute myocardial infarction. PLoS One 2016;11:e0157233.
101. Pedersen SF, Thrysoe SA, Robich MP, Paaske WP, Ringgaard S, Botker HE, Hansen ES, Kim WY. Assessment of intramyocardial hemorrhage by T1-weighted cardiovascular magnetic resonance in reperfused acute myocardial infarction. J Cardiovasc Magn Reson 2012;14:59.
102. Bulluck H, Rosmini S, Abdel-Gadir A, Bhuva AN, Treibel TA, Fontana M, Gonzalez-Lopez E, Ramlall M, Hamarneh A, Sirker A, Herrey AS, Manisty C, Yellon DM, Moon JC, Hausenloy DJ. Diagnostic performance of T1 and T2 mapping to detect intramyocardial hemorrhage in reperfused ST-segment elevation myocardial infarction (STEMI) patients. J Magn Reson Imaging 2017;46:877-886.
103. Robbers LF, Eerenberg ES, Teunissen PF, Jansen MF, Hollander MR, Horrevoets AJ, Knaapen P, Nijveldt R, Heymans MW, Levi MM, van Rossum AC, Niessen HW, Marcu CB, Beek AM, van RN. Magnetic resonance imaging-defined areas of microvascular obstruction after acute myocardial infarction represent microvascular destruction and haemorrhage. Eur Heart J 2013;34:2346-2353.
104. DeFily DV, Chilian WM. Preconditioning protects coronary arteriolar endothelium from ischemia-reperfusion injury. Am J Physiol 1993;265:H700-H706.
105. Ku DD. Coronary vascular reactivity after acute myocardial ischemia. Science 1982; 218:576-578.
106. Lefer AM, Tsao PS, Lefer DJ, Ma XL. Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia. FASEB J 1991;5:2029-2034.
107. Piana RN, Shafique T, Dai HB, Sellke FW. Epicardial and endocardial coronary microvascular responses: effects of ischemia-reperfusion. J Cardiovasc Pharmacol 1994; 23:539-546.
108. Cai Z, Zhong H, Bosch-Marce M, Fox-Talbot K, Wang L, Wei C, Trush MA, Semenza GL. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res 2008;77:463-470.
109. Matsunaga T, Warltier DC, Tessmer J, Weihrauch D, Simons M, Chilian WM. Expression of VEGF and angiopoietins-1 and-2 during ischemia-induced coronary angiogenesis. Am J Physiol Heart Circ Physiol 2003;285:H352-H358.
110. Toyota E, Warltier DC, Brock T, Ritman E, Kolz C, O?Malley P, Rocic P, Focardi M, Chilian WM. Vascular endothelial growth factor is required for coronary collateral growth in the rat. Circulation 2005;112:2108-2113.
111. Heusch G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 2015;116:674-699.
112. Pung YF, Rocic P, Murphy MP, Smith RA, Hafemeister J, Ohanyan V, Guarini G, Yin L, Chilian WM. Resolution of mitochondrial oxidative stress rescues coronary collateral growth in Zucker obese fatty rats. Arterioscler Thromb Vasc Biol 2012;32: 325-334.
113. Heil M, Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res 2004;95:449-458.
114. Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, Opie L. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 2014;383:1933-1943.
115. Hausenloy DJ, Barrabes JA, Botker HE, Davidson SM, Di LF, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes HA, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda R, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado D. Ischaemic conditioning and targeting reperfusion injury: A 30 year voyage of discovery. Basic Res Cardiol 2016;111:70.
116. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
117. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-H588.
118. Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res 2008;79:377-386.
119. Sivaraman V, Pickard JM, Hausenloy DJ. Remote ischaemic conditioning: cardiac protection from afar. Anaesthesia 2015;70:732-748.
120. Pickard JM, Botker HE, Crimi G, Davidson B, Davidson SM, Dutka D, Ferdinandy P, Ganske R, Garcia-Dorado D, Giricz Z, Gourine AV, Heusch G, Kharbanda R, Kleinbongard P, MacAllister R, McIntyre C, Meybohm P, Prunier F, Redington A, Robertson NJ, Suleiman MS, Vanezis A, Walsh S, Yellon DM, Hausenloy DJ. Remote ischemic conditioning: from experimental observation to clinical application: report from the 8th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol 2015;110:453.
121. Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. J Am Coll Cardiol 2015;65:177-195.
122. Heusch G. 25 years of remote ischemic conditioning: from laboratory curiosity to clinical outcome. Basic Res Cardiol 2018;113:15.
123. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic ?preconditioning? protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993;87:893-899.
124. Schmidt MR, Smerup M, Konstantinov IE, Shimizu M, Li J, Cheung M, White PA, Kristiansen SB, Sorensen K, Dzavik V, Redington AN, Kharbanda RK. Intermittent peripheral tissue ischemia during coronary ischemia reduces myocardial infarction through a KATP-dependent mechanism: first demonstration of remote ischemic perconditioning. Am J Physiol Heart Circ Physiol 2007;292:H1883-H1890.
125. Kerendi F, Kin H, Halkos ME, Jiang R, Zatta AJ, Zhao ZQ, Guyton RA, Vinten-Johansen J. Remote postconditioning. Brief renal ischemia and reperfusion applied before coronary artery reperfusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol 2005;100:404-412.
126. Kaeffer N, Richard V, Francois A, Lallemand F, Henry JP, Thuillez C. Preconditioning prevents chronic reperfusion-induced coronary endothelial dysfunction in rats. Am J Physiol 1996;271:H842-H849.
127. Kurzelewski M, Czarnowska E, Maczewski M, Beresewicz A. Effect of ischemic preconditioning on endothelial dysfunction and granulocyte adhesion in isolated guineapig hearts subjected to ischemia/reperfusion. J Physiol Pharmacol 1999;50:617-628.
128. Richard V, Kaeffer N, Tron C, Thuillez C. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation 1994;89:1254-1261.
129. Thourani VH, Nakamura M, Duarte IG, Bufkin BL, Zhao ZQ, Jordan JE, Shearer ST, Guyton RA, Vinten-Johansen J. Ischemic preconditioning attenuates postischemic coronary artery endothelial dysfunction in a model of minimally invasive direct coronary artery bypass grafting. J Thorac Cardiovasc Surg 1999;117:383-389.
130. Gattullo D, Linden RJ, Losano G, Pagliaro P, Westerhof N. Ischaemic preconditioning changes the pattern of coronary reactive hyperaemia in the goat: role of adenosine and nitric oxide. Cardiovasc Res 1999;42:57-64.
131. Li Z, Jin ZQ. Ischemic preconditioning enhances integrity of coronary endothelial tight junctions. Biochem Biophys Res Commun 2012;425:630-635.
132. Bouchard JF, Lamontagne D. Mechanisms of protection afforded by preconditioning to endothelial function against ischemic injury. Am J Physiol 1996;271:H1801-H1806.
133. Merkus D, Stepp DW, Jones DW, Nishikawa Y, Chilian WM. Adenosine preconditions against endothelin-induced constriction of coronary arterioles. Am J Physiol Heart Circ Physiol 2000;279:H2593-H2597.
134. Beresewicz A, Maczewski M, Duda M. Effect of classic preconditioning and diazoxide on endothelial function and O2-And NO generation in the post-ischemic guinea-pig heart. Cardiovasc Res 2004;63:118-129.
135. Kaeffer N, Richard V, Thuillez C. Delayed coronary endothelial protection 24 hours after preconditioning: role of free radicals. Circulation 1997;96:2311-2316.
136. Bouchard JF, Chouinard J, Lamontagne D. Role of kinins in the endothelial protective effect of ischaemic preconditioning. Br J Pharmacol 1998;123:413-420.
137. Bouchard JF, Chouinard J, Lamontagne D. Participation of prostaglandin E2 in the endothelial protective effect of ischaemic preconditioning in isolated rat heart. Cardiovasc Res 2000;45:418-427.
138. Laude K, Favre J, Thuillez C, Richard V. NO produced by endothelial NO synthase is a mediator of delayed preconditioning-induced endothelial protection. Am J Physiol Heart Circ Physiol 2003;284:H2053-H2060.
139. Maczewski M, Duda M, Pawlak W, Beresewicz A. Endothelial protection from reperfusion injury by ischemic preconditioning and diazoxide involves a SOD-like anti-O2-mechanism. J Physiol Pharmacol 2004;55:537-550.
140. Duda M, Czarnowska E, Kurzelewski M, Konior A, Beresewicz A. Ischemic preconditioning prevents endothelial dysfunction, P-selectin expression, and neutrophil adhesion by preventing endothelin and O2-generation in the post-ischemic guinea-pig heart. J Physiol Pharmacol 2006;57:553-569.
141. Kim SJ, Zhang X, Xu X, Chen A, Gonzalez JB, Koul S, Vijayan K, Crystal GJ, Vatner SF, Hintze TH. Evidence for enhanced eNOS function in coronary microvessels during the second window of protection. Am J Physiol Heart Circ Physiol 2007;292: H2152-H2158.
142. Bauer B, Simkhovich BZ, Kloner RA, Przyklenk K. Does preconditioning protect the coronary vasculature from subsequent ischemia/reperfusion injury? Circulation 1993; 88:659-672.
143. Loke KE, Woodman OL. Preconditioning improves myocardial function and reflow, but not vasodilator reactivity, after ischaemia and reperfusion in anaesthetized dogs. Clin Exp Pharmacol Physiol 1998;25:552-558.
144. Skyschally A, Gres P, Heusch P, Martin C, Haude M, Erbel R, Schulz R, Heusch G. Preinfarction angina: no interference of coronary microembolization with acute ischemic preconditioning. J Mol Cell Cardiol 2005;39:355-361.
145. Skyschally A, Gres P, Hoffmann S, Haude M, Erbel R, Schulz R, Heusch G. Bidirectional role of tumor necrosis factor-Alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ Res 2007;100:140-146.
146. Tomai F, Crea F, Chiariello L, Gioffre PA. Preinfarction angina and myocardial preconditioning. Cardiologia 1999;44:963-967.
147. Heusch G. Nitroglycerin and delayed preconditioning in humans: yet another new mechanism for an old drug? Circulation 2001;103:2876-2878.
148. Andreotti F, Sciahbasi A, De ME, Maseri A. Preinfarction angina and improved reperfusion of the infarct-related artery. Thromb Haemost 1999;82 Suppl 1:68-72.
149. Colonna P, Cadeddu C, Montisci R, Ruscazio M, Selem AH, Chen L, Onnis E, Meloni L, Iliceto S. Reduced microvascular and myocardial damage in patients with acute myocardial infarction and preinfarction angina. Am Heart J 2002;144:796-803.
150. Whittaker P, Przyklenk K. From ischemic conditioning to ?hyperconditioning?: clinical phenomenon and basic science opportunity. Dose Response 2014;12:650-663.
151. Zhao JL, Yang YJ, You SJ, Cui CJ, Gao RL. Different effects of postconditioning on myocardial no-reflow in the normal and hypercholesterolemic mini-swines. Microvasc Res 2007;73:137-142.
152. Baranyai T, Giricz Z, Varga ZV, Koncsos G, Lukovic D, Makkos A, Sarkozy M, Pavo N, Jakab A, Czimbalmos C, Vago H, Ruzsa Z, Toth L, Garamvolgyi R, Merkely B, Schulz R, Gyongyosi M, Ferdinandy P. In vivo MRI and ex vivo histological assessment of the cardioprotection induced by ischemic preconditioning, postconditioning and remote conditioning in a closed-chest porcine model of reperfused acute myocardial infarction: importance of microvasculature. J Transl Med 2017;15:67.
153. Bodi V, Ruiz-Nodar JM, Feliu E, Minana G, Nunez J, Husser O, Martinez-Elvira J, Ruiz A, Bonanad C, Monmeneu JV, Lopez-Lereu MP, Forteza MJ, de Dios E, Hervas A, Moratal D, Gomez C, Mainar L, Sanchis J, Mainar V, Valencia J, Diaz A, Noguera I, Chaustre F, Chorro FJ. Effect of ischemic postconditioning on microvascular obstruction in reperfused myocardial infarction. Results of a randomized study in patients and of an experimental model in swine. Int J Cardiol 2014;175:138-146.
154. Zalewski J, Claus P, Bogaert J, Driessche NV, Driesen RB, Galan DT, Sipido KR, Buszman P, Milewski K, Van de Werf F. Cyclosporine A reduces microvascular obstruction and preserves left ventricular function deterioration following myocardial ischemia and reperfusion. Basic Res Cardiol 2015;110:18.
155. Skyschally A, Walter B, Heusch G. Coronary microembolization during early reperfusion: infarct extension, but protection by ischaemic postconditioning. Eur Heart J 2013;34:3314-3321.
156. Mewton N, Thibault H, Roubille F, Lairez O, Rioufol G, Sportouch C, Sanchez I, Bergerot C, Cung TT, Finet G, Angoulvant D, Revel D, Bonnefoy-Cudraz E, Elbaz M, Piot C, Sahraoui I, Croisille P, Ovize M. Postconditioning attenuates no-reflow in STEMI patients. Basic Res Cardiol 2013;108:383.
157. Dong M, Mu N, Guo F, Zhang C, Ren F, Li J, Tao Z, Yang J, Li G. The beneficial effects of postconditioning on no-reflow phenomenon after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction. J Thromb Thrombolysis 2014;38:208-214.
158. Ma XJ, Zhang XH, Li CM, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function in patients with acute myocardial infarction. Scand Cardiovasc J 2006;40:327-333.
159. Eitel I, Stiermaier T, Rommel KP, Fuernau G, Sandri M, Mangner N, Linke A, Erbs S, Lurz P, Boudriot E, Mende M, Desch S, Schuler G, Thiele H. Cardioprotection by combined intrahospital remote ischaemic perconditioning and postconditioning in ST-elevation myocardial infarction: The randomized LIPSIA CONDITIONING trial. Eur Heart J 2015;36:3049-3057.
160. Freixa X, Bellera N, Ortiz-Perez JT, Jimenez M, Pare C, Bosch X, De Caralt TM, Betriu A, Masotti M. Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention. Eur Heart J 2012;33:103-112.
161. Tarantini G, Favaretto E, Marra MP, Frigo AC, Napodano M, Cacciavillani L, Giovagnoni A, Renda P, De Biasio V, Plebani M, Mion M, Zaninotto M, Isabella G, Bilato C, Iliceto S. Postconditioning during coronary angioplasty in acute myocardial infarction: The POST-AMI trial. Int J Cardiol 2012;162:33-38.
162. Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, Vogel M, Sorensen K, Redington AN, MacAllister R. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002;106:2881-2883.
163. Loukogeorgakis SP, Williams R, Panagiotidou AT, Kolvekar SK, Donald A, Cole TJ, Yellon DM, Deanfield JE, MacAllister RJ. Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a K(ATP)-channel dependent mechanism. Circulation 2007;116:1386-1395.
164. Loukogeorgakis SP, Panagiotidou AT, Broadhead MW, Donald A, Deanfield JE, MacAllister RJ. Remote ischemic preconditioning provides early and late protection against endothelial ischemia-reperfusion injury in humans: role of the autonomic nervous system. J Am Coll Cardiol 2005;46:450-456.
165. Luca MC, Liuni A, McLaughlin K, Gori T, Parker JD. Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: A human study. J Am Heart Assoc 2013;2:e000075.
166. Jones H, Hopkins N, Bailey TG, Green DJ, Cable NT, Thijssen DH. Seven-day remote ischemic preconditioning improves local and systemic endothelial function and microcirculation in healthy humans. Am J Hypertens 2014;27:918-925.
167. Hauerslev M, Mork SR, Pryds K, Contractor H, Hansen J, Jespersen NR, Johnsen J, Heusch G, Kleinbongard P, Kharbanda R, Botker HE, Schmidt MR. Influence of longterm treatment with glyceryl trinitrate on remote ischemic conditioning. Am J Physiol Heart Circ Physiol 2018;315:H150-H158.
168. Shimizu M, Konstantinov IE, Kharbanda RK, Cheung MH, Redington AN. Effects of intermittent lower limb ischaemia on coronary blood flow and coronary resistance in pigs. Acta Physiol (Oxf) 2007;190:103-109.
169. Zhou K, Yang B, Zhou XM, Tan CM, Zhao Y, Huang C, Liao XB, Xiao HB. Effects of remote ischemic preconditioning on the flow pattern of the left anterior descending coronary artery in normal subjects. Int J Cardiol 2007;122:250-251.
170. Xu Y, Yu Q, Yang J, Yuan F, Zhong Y, Zhou Z, Wang N. Acute hemodynamic effects of remote ischemic preconditioning on coronary perfusion pressure and coronary collateral blood flow in coronary heart disease. Acta Cardiol Sin 2018;34: 299-306.
171. Corcoran D, Young R, Cialdella P, McCartney P, Bajrangee A, Hennigan B, Collison D, Carrick D, Shaukat A, Good R, Watkins S, McEntegart M, Watt J, Welsh P, Sattar N, McConnachie A, Oldroyd KG, Berry C. The effects of remote ischaemic preconditioning on coronary artery function in patients with stable coronary artery disease. Int J Cardiol 2018;252:24-30.
172. Heusch G. Protection of the human coronary circulation by remote ischemic conditioning. Int J Cardiol 2018;252:35-36.
173. White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, Tehrani S, Flett AS, Meier P, Ariti C, Davies JR, Moon JC, Yellon DM, Hausenloy DJ. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2015;8: 178-188.
174. White SK, Hausenloy DJ, Moon JC. Imaging the myocardial microcirculation postmyocardial infarction. Curr Heart Fail Rep 2012;9:282-292.
175. Bulluck H, Hausenloy DJ. Microvascular obstruction: The bane of myocardial reperfusion. Rev Esp Cardiol (Engl Ed) 2015;68:919-920.
176. Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, Schulz R, Erbel R. Coronary microembolization: from bedside to bench and back to bedside. Circulation 2009;120:1822-1836.
177. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: A new paradigm for myocardial preconditioning? Cardiovasc Res 2002;55:534-543.
178. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 2003;60:617-625.
179. Skyschally A, Schulz R, Heusch G. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 2010;24:85-87.
180. Hausenloy DJ, Boston-Griffiths EA, Yellon DM. Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol 2012;165: 1235-1245.
181. Lim WY, Messow CM, Berry C. Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: A systematic review and meta-Analysis. Br J Pharmacol 2012;165:2034-2043.
182. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481.
183. Cung TT, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D, Bonnefoy-Cudraz E, Guerin P, Elbaz M, Delarche N, Coste P, Vanzetto G, Metge M, Aupetit JF, Jouve B, Motreff P, Tron C, Labeque JN, Steg PG, Cottin Y, Range G, Clerc J, Claeys MJ, Coussement P, Prunier F, Moulin F, Roth O, Belle L, Dubois P, Barragan P, Gilard M, Piot C, Colin P, De PF, Morice MC, Ider O, Dubois-Rande JL, Unterseeh T, Le BH, Beard T, Blanchard D, Grollier G, Malquarti V, Staat P, Sudre A, Elmer E, Hansson MJ, Bergerot C, Boussaha I, Jossan C, Derumeaux G, Mewton N, Ovize M. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med 2015;373:1021-1031.
184. Ottani F, Latini R, Staszewsky L, La VL, Locuratolo N, Sicuro M, Masson S, Barlera S, Milani V, Lombardi M, Costalunga A, Mollichelli N, Santarelli A, De CN, Sganzerla P, Boi A, Maggioni AP, Limbruno U. Cyclosporine A in reperfused myocardial infarction: The multicenter, controlled, open-label CYCLE trial. J Am Coll Cardiol 2016;67: 365-374.
185. Bibli SI, Papapetropoulos A, Iliodromitis EK, Daiber A, Randriamboavonjy V, Steven S, Brouckaert P, Chatzianastasiou A, Kypreos KE, Hausenloy DJ, Fleming I, Andreadou I. Nitroglycerin limits infarct size through S-nitrosation of Cyclophilin D: A novel mechanism for an old drug. Cardiovasc Res 2019;115:625-636.
186. Herring MJ, Dai W, Hale SL, Kloner RA. Rapid induction of hypothermia by the ThermoSuit system profoundly reduces infarct size and anatomic zone of no reflow following ischemia-reperfusion in rabbit and rat hearts. J Cardiovasc Pharmacol Ther 2015;20:193-202.
187. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 2014;66:1142-1174.
188. Wang WZ, Jones S, Stepheson LL, Khiabani KT, Zamboni WA. Microvascular protection induced by late preconditioning was abolished in STZ-induced acute diabetic rats. J Reconstr Microsurg 2002;18:689-696.
189. van dM I, Riksen N, Seeger JP, Schreuder TH, Borm GF, Eijsvogels TM, Hopman MT, Rongen GA, Thijssen DH. Aging attenuates the protective effect of ischemic preconditioning against endothelial ischemia-reperfusion injury in humans. Am J Physiol Heart Circ Physiol 2013;304:H1727-H1732.
190. Nakamura S, Kimura M, Goto C, Noma K, Yoshizumi M, Chayama K, Kihara Y, Higashi Y. Cigarette smoking abolishes ischemic preconditioning-induced augmentation of endothelium-dependent vasodilation. Hypertension 2009;53:674-681.
191. Moro L, Pedone C, Mondi A, Nunziata E, Antonelli Incalzi R. Effect of local and remote ischemic preconditioning on endothelial function in young people and healthy or hypertensive elderly people. Atherosclerosis 2011;219:750-752.
192. Kono Y, Fukuda S, Hanatani A, Nakanishi K, Otsuka K, Taguchi H, Shimada K. Remote ischemic conditioning improves coronary microcirculation in healthy subjects and patients with heart failure. Drug Des Devel Ther 2014;8:1175-1181.
193. Liuni A, Luca MC, Gori T, Parker JD. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase-2-dependent mechanism. J Am Coll Cardiol 2010;55:1002-1006.
194. Liuni A, Luca MC, Gori T, Parker JD. Loss of the preconditioning effect of rosuvastatin during sustained therapy: A human in vivo study. Am J Physiol Heart Circ Physiol 2012;302:H153-H158.
195. Okorie MI, Bhavsar DD, Ridout D, Charakida M, Deanfield JE, Loukogeorgakis SP, MacAllister RJ. Postconditioning protects against human endothelial ischaemiareperfusion injury via subtype-specific KATP channel activation and is mimicked by inhibition of the mitochondrial permeability transition pore. Eur Heart J 2011;32:1266-1274.
196. Przyklenk K, Maynard M, Greiner DL, Whittaker P. Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes. Antioxid Redox Signal 2011;14:781-790.
197. Liu X, Sha O, Cho EY. Remote ischemic postconditioning promotes the survival of retinal ganglion cells after optic nerve injury. J Mol Neurosci 2013;51:639-646.
198. Kwong W, Liuni A, Zhou K, Parker JD. Cyclooxygenase inhibition and rosuvastatininduced vascular protection in the setting of ischemia-reperfusion: A human in vivo study. Vascul Pharmacol 2015;71:159-165.
199. Kwong W, Parker JD. The effect of clopidogrel on the response to ischemia reperfusion. J Cardiovasc Pharmacol Ther 2017;22:368-373.
200. McLaughlin K, Lytvyn Y, Luca MC, Liuni A, Gori T, Parker JD. Repeated daily dosing with sildenafil provides sustained protection from endothelial dysfunction caused by ischemia and reperfusion: A human in vivo study. Am J Physiol Heart Circ Physiol 2014; 307:H888-H894.